The renalretention and insulinoma targeting properties of these new exendinanalogues labeled with 68Ga or 177Lu have beenevaluated in a xenograft mouse model bearing subcutaneous GLP-1R-expressinginsulinomas. This evidence concerns the gene GLP1R and pancreatic insulinoma.